STUDY	BR.EF	CLINICALTRIALS.GON IDENTIFIER	V SPONSORS AND COLLABORATORS	STUDY START DATE	STUDY COMPLETION DATE	POSTED	LAST UPCOATE POSTED	INVESTIGATORS	CONTACTS	их
Bone Marrow Hesenchymal Stem Cell Derled Extracellular Vesicles Infusion Treatment for ARDS (DXIT-ARDS)	To evaluate the taffety and efficacy of intravenous(N) administration of boxe marrow mesendymal demousl derived extraordillar veidelet(N), Garlia, as transmet for Acute Respiratory Distress Syndrome.	NC705127122	Direct Biologics, LLC	: 110-23	ian-23	19-Nov-21	10-5ep-22	Vikram Sengupta,MD Direct Biologics	Heid Maran 800-793-1021 hmaran@directhiologics.com	
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepaia	The aim of this study was to determine whether sivelents sodium has a potentive effect on ARDS in patients with septis.	NCT04973670	Southeast University China	11-041-21	30-0c1-23	22-346-21	3-Jan-22	uwing, MDbegartment of Critical Care Medicine, Zhangda Hospital, School of	Contact: Liu ling, MD+86-25- 81262553534ingdoctor@126.co m Contact: Yang yi, MD+86-25- 812625533yiyiyang2004@063.co	nama tha shunar bias a titl a basa titl yan fa'la tao mataina
			Same Marrie					Medicine, Southeast University Marcelo &P Amato, PhdDepartment of	m Contact: Josepim HD Knox, Buc2125229009 ext	
Efficacy and Safety Evaluation of B22173B in ARDS Patients	The purpose of this study is to evaluate safety, talenability and efficacy of #22118 is insubated parients with severe Acute Repiratory Distress Syndrome.	NC705384379	sporc Biozeus Biopharmaceutical S.# Call: InCor Heart Institute	L Nov-22	Nov-23	20-May-22	10 Aug 22	Cardio-Pulmonar, Pulmonary Division, Hospital das Olinicas, University of São Paulo	+SSpaquim knos@blozeuc.com. br Contact: Gabriela Westerlund, Phd11252080 est +SSgabriela westerlund@blozeu u.com.br	. Beny mining in a definite a definition of the size o
Bone Marrow Mesenchynal Stem Gell Derived KVs for COVID-19 Moderate-to-Sovere Acate Respiratory Distress Syndrome (#RDS): A Phase III Cinical Trial	Extraoreurar vesce imusion as Early Goal Diversed Therapy for COVID-9 related ARDS (EXTINGUID COVID- 16) is a multicenter, double-blinded, plasabo-cantrolled, randomized clinical trait to evaluate the 4 Microsy of Earlis in treating moderate to severe ARDS caused by	NC705354141	Direct Biologics, U.C.	1-Jul-22	3-346-23	29-Apr-22	30-Aug-22	Vikram Sengupta,MD Direct Biologics	Heid Moran 800-791-0021 hmoran@drestbiologics.com	Ber Neuerhausbach ins Schlausbilt is 1996 in Margan International Johns 1997 i Rast Dan Tar La Tartage, Bastingan,
inhalational (Sevofiarane) Versus Intravencus (Propoful) Sedation in Adults With a Moderate Form of ABO ⁴	The pointary objective for the matricentral INVARIA Trial will be to determine the effects of inhibitional pseuflatures versus intravenous (propolo) undation on ρ/F ratio on the second day, hospital inortality and (CD) (preceive one unit), and in-hospital length of trans in	NC705259631	Negovsky Rearimatology Resear Institute	zh 14-Mar-32	25-Feb-26	28-Feb-22	5-Apr-22	Valery Likhvartsev Negovsky Reasimatology Resignet Lordon	Contact: Valery Likhvantee+790362259921kd7 64@gmail.com Contact: Levan	Adation for directions are an application and all a laboration of the Life balance. Classifier gas
Pirfesidane to Prevent Fibrosic in Ards. (PICMER)	adults with a moderate form of ARDS. This is a randomized controlled mudy to evaluate for the first time the efficace of Picheoidone in ARDS.	NC705075061	Liniversitä Vita Saluto San Raffaele	° 003-34	0ct-25	12-0ct-21	27-Dec-22	Govanni Landoni, Profesorivita Galute San Roffaele	Berikaduli - 79263200968b.be 	Mandau na Barra (Barra a da Sa Mala Barra) (Barra) da se
			Sponsor: Nantarg Hospital of Southern Medical					University	Contact: Giacomo Monti,	
Effect of Early Transment With Sivelector Sodium in ARDS Patients (do-ARDS)	This study is a multicenter, prospective, downational cohort multi, The subjects were patients who developed ABDS within the proceeding 72h.	NCT06630350	University Collaborators Sherahen Hospital of Southern Medical University Guangdong No.2 Provincial People's Hospital Foshan Hospital of Traditional Chinese	f 30-5ep-21	35.4ug-23	25-Aug-21	21-040-32	Southern medical university Hanfang hospital Guangshou, China, So0525	2	Berdin have being idea in being idea in the second an
Efficacy of Canvenoue as add-on Treatment in Moderate to Seven ARDS in COVID-18 (MINECRAFT)	The main aim of the dudy is to estimate the potential efficacy of its converse as address therapy on maximal efficacy of its converse states and the states alone in transition moderners or overwee ARDs due to SARF-Gav-2.	NCT04977960	Spansar: Fondacione IRCCS Ca' Granda, Oxpedale Maggiore Policinico Collaborator: Universit of Milan IRCCS Aslenda Oxpedaliero- Universitaria di Rologr	ty Sep-22	Dec-22	July 27, 2021	i 20-May-22	Marco Viceral, MDFondazione RCCS Car Granda, Ospedale Maggiore Polidinico	Marco Vicensi, Mb + 38035503557 marco.vicensi@goliclinico.mi.it	Manu af Samana a salar bandara sa banana ARI a (1912 at Jackara an Anadhainan
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis	The aim of this study was to determine whether siveletat sodium has a protective effect on ARDS in patients with upple.	NCT08973670	Southeast University China	11-08-21	38-0ct-23	22-346-31	3-389-22	Liu ling, MDDepartment of Critical Care Medicine, 2hongda Hospital, School of Medicine, Southeast University	Contact: Liu ling, MD+86-25- 82262553514/ingdoctor@126.co m Contact: Yang yi, MD+86-25- 822625523yipiyang2006@568.co m	Andre Che d'Andre Male a Male a Male and a d'Andre Che Che Che Che Che Che Che Che Che Ch
Treatment of ARDS With Sivelectat Sodium (TDAWSS)	Therefore, this study was intended to evaluate the efficacy of sivelestat sodium in the treatment of ARDS patients with DBE in a multicenter randomiaed controlled clinical trial	NCT24909687	Sichuan Provincial People's Hospital	18-Apr-22	35-34-24	2-Jan 21	19-Apr-22	Xiaobo Huang,MD Sichuan Academy of Medical Sciences	Hongli He, Ph.D. +86- 28-47293633 hhi0408@163.com	Tanana di King Kanalana da ka
Effect of Two Different Dates of Decastoribution in Petiatrix Web ARDs and COVID-19 (REMIC)	AND is projectiva, prive 1, generale, monitoria del regio e agrico del prive del prive del monitoria del Prive de la Prive del arte tuto del construcción del prive del prive del prive del construcción del prive del prive meter del prive del prive.	NCTORAGESSES	Sponor Biro to transmitty in trajectory Calabourance Matanyk Luiventy Vanadar surgery, Usiventy kopatis Residue Vanahady Prage Garan Luivenzy Hospital Octowa St. Anne's Ubieventy Hospital Anne's Ubieventy Hospital Anne's Ubieventy Hospital Bark Rejiona Hospital Mittany similarity Hospital Praha	ni 34eb21 4	304pr-23	114ec-20	3-Mar-22	2	Jan Halida, HO, PHO, EDC +0072334903 jacmakadgenat.com Jan -005272009 jantasak@centum.c2	
Treatment With Pirfesidone for COVID-19 Related Severe ABDS	A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nanogestric table or orally as 802 mg Tib Tir 4 weeks in addicion to Standard of Care (SoC), omgested to Soc Jahon, in a population of CDVID-09 induced severe ARDS.	NC704653821	Sponsor: Saraka University Medical Center Collaborator: Roche Pharma AG	8-Nov-20	Dec-22	40ec-30	27-Juli-22	Ori Galaree, HDICU physician in SMC	Yasmeen Abu Fraika, Saroka University Hedical Center	
Study to Find the Highest Safe Done of Soluble Guanylate Cycluse (cc) Activator, BAY 1211168 Administered as Naligh Dones by inhalation to Patients Who Cannot Rwathe by Their Own and Saffer Finm a Type of Long Fallerer What Causes Field to Build up in the Lungs Naling Breathing Difficult (AROS)	With this study researchers want to find the highest usle does of the soluble docarytate Cyclaus (UCC) Activator, RV 212158 and how calls and well the study drug works.	NCT04620943	Sponsor: Bayer	24-Nov-20	28-346-22	30-0ct-20	3-349-23	2	Bayer Clinical Trials Contactjejs- 888-84 22997clinical-trials- contact@bayer.com	
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ABOS Suring COMD-19 Pandemia (LidoCovid)	The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of intravenous ideating on a sectange and inflammation in acute requiremy distress systeme (pMBS) due or not to Cavid-18 pneumonia.	NCT04609865	University Hospital, Strasbourg, France	4 Nov-20	Feb34	30-0ct-20	18-Aug-22	,	Thiên-Nga Crianakauto-TRAN, MD3 88 12 70 81 eet 0022thierega chamaraan tranifichra-etraboarg fr	
This Study Collects Information on this Safety of Inhulus Pergylated Advanced IIIIn JPS6-AdAII, How tha Dray in Tolecards and How I at Alfreds patient Para Cause Field to Build up in the tange Making Investing Difficult (ARDS) (SEAL)	The study is campood of test port. In get A diff and to assist out of binding applicated antenneetable pick-facility of the study of the additional pick-facility of the study of the therappect effect of the study of the study the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the study of the study of the higher data with the higher data with the study of the study of the higher data with the higher data with the study of the higher data with the higher data with the study of the higher data with the higher data withe	NCT04417036	kayer	7-sul-20	31-0ec34	61an 20	10-18-33	2	Bayer Clinical Triats Contam)-(5- 888-64 22837clinical + triats- contact@bayer.com	n Data dan darah um dar dan dan kana dan Ki Dil ba da a Sendari ba dan dan tar bartar tar bartar tar ba dari bir a se an bir barta dar bir dan bir bir dar bir bir bir dar bir bir bir dar bir bir bir bir bir bir bir bir bir bi
A Study of the CR whibitor AANY OZ is Patients With ARDS Due to COVID-19 (SAVE) (SAVE)	The study is a prospective, randomized, placeba- controlled, single-blind phase 2 clinical study of the efficiary and study of AMH-001, a potent C inhibitor, for the management of patients with ARDS caused by SAR6-CoV-2 inflation.	NCT04285456	Anyıdas Plarmaceuticalı S.A.	Sep-21	0ec-22	20-May-20	21-feb-21	2	No Contacts or locations Provided	A T-a - d'an Channe ains an Anna ann Anna Anna Chan Chan Chan Chan Chan Chan
Evaluating AVMEPO2 for Treatmen of CONTO-19 or Influence-execution ARDS (AVMEPO2)	The study is designed to evaluate the callety, tolerability, and pharmaphinetics of single does of Avth07503 in these ARDS patients.	NCT04366115	Spansor: AVM Biotechnology III Callaborator: Medpace, Inc.	1 1-0ec-32	1-Mar-35	28-Apr-20	74eb-22	3	Contact: Janet R Rea,MSPH2268668922/rea@uv mbiotech.com Contact: Mia Lor22668069922mior@uvmbiote ch.com	(and all a balance) is the second of the second sectors () is the second second
Safety and Proliminary Efficacy of Sequential Multiple Assending Dones of Solvation to Treat Pulmonary Premeability Oxdensa in Patients With Moderate-to-enviro ARDS	This phase tilty randomised, phasebo-controlled, double- blind, dose esculation study will source the local and spreenic callery of 7 days carily inhaled sequential multiple assending doses of aduration in patients with painnaras presentably or dense and moderate- neuren AGGs and review potential efficacy endpoints for a fareway phase ill adurata fail.	NCT08567577	Apoptics Forsthung un Entwicklung GmbH	nd 23-May-58	i jun-23	26-iun-18	6-Aug-22	÷	Bernhard Fischer, Prof. Dr. 2013 664542 est 2959b.fischer@apeptica.com	lain an bainne allan a' searth bain sandar bar fainch a lar banna bannah bainn a bean ath bainn san ath bainn an
influence of NEP inhibition on Vencular Lask and influenzation (NEPI-DELAMMATION)	The aim of this experimental medicine study is to assess the effect of using the licensed MP inhibitor Racecadotril, in a well-established, safe model of inflammation-induced aim literars in healthy human volunteers to determine piranally whether the fluid azamutation i.e. leak, in these bilizers is reduced by to statege with his draw	NCT05600062	Queen Mary Universit of London Medical Research Court	ty 16-Jan-22 sdl	15-Mar-34	31-0ct-22	10-Nov-22	Adrian HobbsQueen Mary Utileensty London	Aemun Salam, MBBS, MRCP, FFICMINEOODSDaemun sala m@qmsLac.uk	stema ADI status manda un artekonom 200 di statu Tag La Tarana. Anna fan pa
Pierlaafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) (LEONARDO)	to assess the therapeutic efficacy and safety of Plenkafor in patients	NCT05411575	Kiving Bistech	19-346-32	Jun-23	9-Jan-22	9-Nov-22	3	Information provided by (Responsible Party): eP-Ptarma (42king Motech)	Reads and least a line base based and a first the Station Stations
A Phase 2to Multi-Center, Randonived, Double-Blind, Hasebo- Controlled Study, Evaluating Efficacy and Safety of Allocato-Official In Stratest Wolf Severe or Critical COVID-19 With Associated Ause Respiratory Distress Syndrome (ARDS)	This is a Plase 2b multi-ortext, randomized, dioble- biling, planeboardshid may evaluaring the effaces, and altery of microweak (V) (Alternat, 15: black+0 onlis x planebo (1:1) is addr. beaptished patients: when were or original consolvius. Biosas 20(6) (200-01) with associated acute registratory distress syndrome (pMDG).	NCT04922967	Enlives Therapeutics in	11. 16ep21	L SéepJ	3 15449-21	30 Aug 21	Oren Hershkovitz, PhDGslives Therapeutics RED	cccdiren perhaps?	Lang has been been been been and a later they start films of them at her a first NO 2 and her so, been been NO 12 by 19, Contains
Direct Topical Lung Tà Treatment to Improve Outcome & Sequelae af COVID-19 Acate Registrory Distrect Syndhome	Of with dreat topical long instilled T3 therapy for parties	NCT04725150	University of Minnespatis, Minnesp United States, SSL10 Contact: Kielly M McContok kmmccorm@wm.edi	a, 29-02-19	Mar 34	26129-21	6-5ap-22	Principal investigator:Timath y P Rich, MDUniversity of Minnesata Study Chair/David logbar, MDUniversity of Minnesata	Contact: Kelly McConnick, Milla, McLict XXXXII Simmetormaljiu mn.edu Contact: Melika Balleyds 2024 Child Zhalei ROLlyu mx.edu	Real hand an 11 hannel himse himse himse Aller of 100 K Ann hanne himse honor an 16 han an .
The ARCTIC Trial: Aerosalized Ishaled Adenosine Treatment in Patients With Acate Respiratory Distress Syndrome (RKDS) Caused by COVID-19	This is a phase II study to test a denoise efficacy for down-regulation of the overwhelming inflammation of COVID-00 in the lungs as reflected by clinical recovery of lung function; restations of clinically relevant markers of lung function, and resolution of systemic markers of inflammation and cangulation.	NCTORERBORI	University of Florida	Sep-21	Dec-22	18-03-20	17.8ag-21	Principal Investigator:Bruce Spinotiniversity of Florida	Any Gamett(KS) 273- Bhliagamett@anest.ult.edu	The NY Tork for sharehold and the same to be same that an input on the State State (State State
GM-CSF Inhalation to Prevent ARDS in COVID-19 Preumania (SI-COVID)	To assess the safety and tolerability of inhaled molgramozin rebuilior solution in patience with CDVID-59 pneumosia.	NCT04569877	University of Geosee	265ap-20) 30-Dec-J	2 30 Sep-20	1 22-iun-22	Principal Investigator Susann e Herold, Prof. Dr. Universitätsklinik um Giessen und	7	And an end of a list data and a strategy and a
Isbaled Avigtadi for the Testment of COVID-19 in Parients at High Kish for ARDS	Avigtadi, which is a synthetic form of Human Vasoartike intestinal Polypeptide (VP), might be bendicial in patients at nik of developing ARDS. Nondinical studies demonstrate that VP is highly concentrated in the lung, where it reduces inflammation.	NCTORSA6350	Prof. Dr. Järg Leuppi, Cantonal Hospital, Roselland	18-May-21	Dec-32	2-6ap-20	28-tun-22	Principal Investigator Jörg D Läuppi, Professorklantansopit al Raselland	Contact: Jörg D Leuppi, Professor+61 65 925 218kijorg Leuppi Birkstr.ch Contact: Kristin Abig Birkstr.ch	aland kapat di na Nannar di Mali di a Bana na digi di di a Mali di An Dan Tana Bana di ang
Efficacy, Safety, Tolecability, and Biomarkers of MN-166 (Budllact) In Patients Hospitalized With COVID-19 and at Rick for ARDS	The study aims to evaluate MH+ G66 (Buddlast) in patients with CDHID 59 who are at risk of developing acute respiratory distress syndrome.	NCT04428555	MedicNova	11-Jan-21	1-0ec-22	12-Jun-20	25-Aug-22	Study Chair Kacuko Natsuda, MD PhD MPHMedicinova Inc	7	Bang bag bagang antanan dikin panan kanan papanan kanan kanan dari kanan dika dika dari kanan dikan dika dika d
Efficacy and Safety of Anglotensin II Use in Connaviou Disease(COMD)-19 Patients With Acute Respiratory Distress Syndrome (ACEG)	aure in patients with COVID-56, acute severe long injury,	NC704408326	Guy's and St Thomas Neti Foundation True Australian and New Jasland Intensive Can Research Centre Monash Lisivensity Royal Surrey County Royal Surrey County Rogatal Neti Foundati	r 1 1-Jun-20 Ian	35-Dec-32	29-May-20	4Aug21	Principal Investigator/Mariles OttermaneDegartm ent of Ortical Care, Guy's & St Thomar' Hospital	Contact: Marlies Octemmann, MD, PhD0064 200 188 2038Marlies Cheromano@get.n hu.k Contact: Nuttha Lumiertgul.MD, PhD0064 201 188 2038Nuttha Lumiertgul@get.n bi +4	Same witche die sonne ten internet internet Weit (Diesen ist was besiten internet internet in die ten die Statisticae).

Treatment of ARDS With instilled Y3 (ARDS+T3)	It is hypothesized that inclusion of (Ti) into the angupon will increase alwester fluid detarance is presents with ARGs considing in reduced entrywander long water (DVM).	NCT04115514	University of Minnesotz	a 21-02-19	10-017-23	4-02-19	305-22 1	Principal nvestigato: Timoth y 9 Rich, MDunisercitry of Minnesota zudy Chair Chavid H ingbar, MDunisercitry of Minnesota	Contact: Kelly M McCornick, MBA, MSG51363483453kmmczorm@u mn.edu Contact: McMika A Balley, MS6125243457balle867@umn. edu	
A Dose-Ranging Study to Determine the ETFLocy, Safety and Tolerability of AeroFact	The purpose of this two-pert Plane 2 study is to assess the string, talenability and efforts, of asroualized SF-B 1 (AeroFact) when dilivened via nGAM at two different doars	NCT03969992	Aerogen Pharma Limited	4-Mar-20	35 Aug 24	31-May-19	23-Feb-22 5	tudy Director-Andy Clark, PhDAerogen Pharma Carp	Contact: Judy Doto, RH, Böhleb- 796- 9628ijudydotoganongenpharma contact: Jeanette Assein, MSESS422- 1177jaoseingtarrogenpharma.c am	tan kana bara baran na Kana tahu na tanàna dia karina dia dia dia dia dia dia dia dia dia di
Inhaled Dornaas Alpha to Reduce Respiratory Fallure After Severe Trauma (IRAUMADORNASE)	The primary objective is to demonstrate a reduction in the indisence of moderate to severe ABGS is severe travers patients during the fort seven KU days from effort to J0% by providing seronalized domase alth once during the first two consociative KU days and compared to equivalent provision of planeto (NaC) 6/NG.	NCT03368092	University Hospital, Straibourg, France	6-Mar-09	i dec di	11-0eo-17	814-22	2	Contact: Julien POTTECHER, MD=32 208127006julien.pottecher@chr u-strasbourg.8t	täärlinna tään käänny lään kiriana hann jä kuriya. Baattaina
Improvement of Pulmonary Insufficiency After Aartic Dissection With Silvelettat Sodium (PAADSS)	On the basis of not terminating and changing the original treatment plans, silveletars todum was added in the periodynamic period to observe the indexes, and severity of ALL(MOD is the perioperative period. This much is a Revolutional Develophiloded Elevabo-	NCT05343238	First Affliated Hospita X'an Jactorg Universit	il 20-Apr-22 ty	35-Dec-24	25-Apr-22	1 25-8pr-32	tudy Chair:Tao Shi, PhDFirst Affiliated Hospital of Xian Liaotong University	Contact: Tao Shi, Phb0086-029- 85222601th/2008tao@163.com Contact: Tao Ma, Phb0086-029- 85222866mutaodr@163.com	nenner 27 men inden ihr leit heide Withants leite. Miterier, Stoffwar,
A Study to Evaluate the Safety and Effect of STC234 injection Continuous Influion in Subject With Acute Respiratory Distress Syndrome	controlled Phase Ib Study to Evaluate the Safety, Tolerability and Phanmacoli netics of STCEIs Injection Administered as Continuous Intervensus Influion in Chinese Patients with ARDS (Acate Registatory Distress Syndrome).	NCT05000671	Sponsor: Grand Medical Phy Iod. Collaborator: Grand Pharmaceutical (China) Co., Iod.	L 28-Jul-21 1	Dec-22	11-Aug-21	December 27, 2021	,	iames Pang, PhD=61 666555916jpang@grandpharma _2h	te de la construite en très que construit a subject de la construit de la Construit de
Efficacy of Cammon+ as add-on Treatment in Moderate to Seven ARDS in COND-18 (MINECRAFT)	The main aim of the Budy is to estimate the potential efficacy of its concentrate as data on therapy on maximal medical treatment versus maximal medical treatment atome is treating maderate to server ARDS due to SAMS-COV-3.	NCT04977960	Fondazione IRCCS Ca' Granda, Ospedale Maggione Polidinico University of Milan IRCCS Asienda Ospedaliero- Universitaria di Bologra	Sep-22	Dec-23	27-346-21	20-May-22	Principal nvestigator Marco Vicensi, MDFondacione IRCCS Ca' Granda, Dupedale Maggiore Policlinico	Marco Vionel, MD-180255012537marco vicen zi@policinico.mi.it	Stan of Annana as a the Thermat A Mahara Science (MC is Statistic as Charlington)
Protective Effect of Silvelettat Sodium on ARDS in Patients With Septis	Sweletzt codum has been approved for use in patietes with SMS and AU, but whether it can protect patietes with sepair from developing AMS remains unknown. The sim of this code was to determine whether developing addumt has protective effect on ARS in patietes with sepair.	NCT04973670	Southeast University, China	11-03-21	30-0st-23	22+46-25	3 3120-22	itudy Chairtika ling, MDDepartment of Critical Care Medicine, Zhongda Hospital, School of Aedicine, Southeast University	Contact: Liu ling, M2+86-25- 82252525144/regdoctarr@126.co m Contact: Yang yi, M2+86-25- 822625523/rjiyiyang2008@658.co m	
Treatment of ARDS With Sivelettat Sodium (TDAWSS)	this study was intended to evaluate the efficacy of solvientst sodium in the treatment of ARBS patients with SRS in a multioneter randomized controlled clinical shall	NCT04909687	Sichuan Provincial People's Hospital	18-Apr-22	30-14-24	2 (un 21	19-Apr-22	Principal nvertigator Xiaobo Huang, MDSichuan Kcademy of Medical Sciences	Hongli He, Ph.D. 486-28- 872936331NI0408@563.com	
Effect of Two Different Danas of Decomplyance in Proteins With Address of Conto-un planets)	KMDD is a properties, plane 4, que table, and a second sec	NCT04662555	Erno University Hospitz Masayi Lüversity Yasakar araşınıy, Lüversity hospital Krisleviki Vashradıy, Pragae General Lüversity Hospital Düversity Hospital Düversity Hospital Düversity Hospital Düversity Hospital Comma University Hospital Comma University Hospital Comma University Hospital Hospital Hospital Hospital Hospital Hospital Hospital Hospital Hospital Hospital Hospital Hospital Hospital	al 24eb21 el	30 Apr 23	11-0ec-20	3-86ar-32	2	Contact: Jan Matikka, MD, PhD, EDC-202222Hattiganamian anggentation (EDC-60522220Matikanamian) @anteruma	De d'arthur ber d'annéen Marin Brathain (1938) a 18 ann an Anna
Treatment With Pirfenidone for COVD-19 Related Severe ARDS Study to Find the Highest Safe	A randomized, open label, two arm, pilot trial of Prinsidone 2,403 mg administened per susquartic tabe or orally a skitzing ThD for 4 weeks in addition to Standard of Low (EGC), compared to SGC allow, in a population of COVID-18 induced severe ARDS	NCT04652821	Soroka University Medical Center Roche Pharma AG	\$-Nov-20	Dec-22	December 4, 2020	27-346-22	Principal Investigatorsbri Galante, MDICU physician in SMC	7	Sanner Militärin In Old Alkonstans UK Latterne. Stadilaren
Dose of Soluble Guanylate Cyctase (sCc) Activator, BAY 201163 Administrem as Melliph Doses by inhabition to Patients Who Cannot Einathe by Their Own and Saffer Form a Type of Lung Falure That Cauces Fluid Build up in the Lungs Halog Breathing Difficult (ARDS)	With this study researchers want to find the highest safe date of the stubile Gamyster Cyclaw (sGC) Activator, BAY 1211583 and how safe and well the study drug works.	NCT04629943	Rayer	24 Nov 20	28-34-23	30-0ct-20	3-189-22	2	Rayer Clinical Triais Contact(+)5- 888-88 22987clinical triais- contact@bayer.com	
Impact of Intravenous Lidocaine on CEInical Outcomes of Patients With ARbS Burley COVID-19 Pandemia (LidoCovid)	The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of instaveneous blockies on gas exchange and inflammation is acate requiratory distress syndrome (kRdS) due or not to Cavid-til pneumonia.	NCT04609865	University Hospital, Strasbourg, France	4-Nov-30	Feb-34	30-Oct-20	18-Aug-22	,	MD2 88 12 70 81 est 0022thieneg	ner forsener e her a flore heren officer with All here first all here is. Let be the flore flore an
Mesonchymal Stromal Cell Therapy For The Tinatmont Of Acute Respiratory Distress Syndrome (ARDS-MSC-205)	This is in open laber, adde exclusion and the second of the advanced therapy investigational medicial product (k1MeV) exAMC-42-30s, where patients disprased with ARAC coV-3-balanced severe acare registratory dismost repediume (k40C), according to the lawin behavior, and who are on registrator/versitator (and genomenously in this protocal) sopport due to requiratory insufficiency with or without committee distances problems.	NCT14447823	Uppsala University Uppsala University Hospital	17-Jun-20	une 38, 2025	25-Jun-20	22-0ec-22	Principal Investigator:Occar Simonscon, MD, PhDisposita University	7	standyne: Smer (2d Sterg for Schartmed Batel kepterg Steve Johnson Jahl Schartmen, Steinfleidinge,
This Study Collects Information										
on the Safety of Inhaled Pegylated Advenced allia (PEG- ADM), How the Drug in Safetated and How it Affects Patients Soffwing From a Type of Lung Failure That Cauce Flaid to Build up in the Lungs Halling Breaching Difficult (ARDS) (SEAL)	how well patients utiliering from Acate Registatory Distress Syndrome (ARGS) respond to treatment with ishained paylisted advecemental in (PGA RDH) compared to treatment with placebo	NCT04417036	Bayer	7-aui-20	35 Dec 34	4Jan20	10-Jan-23	2	Contact: Report Clinical Trials Contact(+)14888-84 22987/clinical-trialo- contact@bayer.com	This has defensioned in the defended and advantage of the state of the state of the form
on the Safety of Inhaled Perglisted Advancedskills (PCC ADM), How the Drug is Talerated and How It Affects Parison Safeting From a Type of Lang Palane That Cancer Faids to Build when the Lungs Hadrig Forwarding Official (Add Safety A Study of the C3 Inhalitar AMF- 100 in Patients With Add Schurt Covin-10 (SANE) (SANE)	New will partners: unfliving from Acce Respiratory Distructs payloame (MAGS) responds to resurrence with instruct pagegrication showmound in (FoCA DM) compared to transmere with pilocido The study is a prospective, randomised, pilocido emoritade, range-bitled piloux 2 distribution emoritades, range-bitled piloux 2 distribution factors and subject in MAGS caused by SLESE-OV a Institution.	NCT04127036 NCT04285456	Bayer No Contacts or Locations Provided	7-34-20 Sep21	33 dec -34 Dec -22	4-Jan 20 20-May 20	20-Jan-23 21-Feb-21	2 Responsible Party-Anyodas farmaosuticals S.A	Contact: Reyer Clinical Trials Contact)+1488-94 23822clinical trials- contact@bayer.com No Contacts or Locations Provided	
en fin Safriy of Inhalds Register A downed kills (FEC and New 1 Adfects Patients Saffeing Fina y yee of Lang Pahara Nin Cases Plad to Bale Resulting Official (Add S) (SAA), A Study of Hit Cases (SAA) Safety Safety (SAA), A Sadra of Hit Cases (SAA) Safety Safety (SAA), A Sadra of Hit Cases (SAA) (SAA), A Sadra of Hit Cases (SAA) (SAA), Safety Safety (SAA), Safety Safety (SAA), Collarising Khall (SAA), Safety (SAA), Safe	Inter our operation of the program of the sector of the se	NCT14417036 NCT34285456 ClinicalTrink.gov Identifier NCT34366115	Bayer No Contacts or Locations Provided Sposor: AVM Konstronology to Caliaborator: Medjaco, Inc.	7-348-20 Sep-21 6 1-0ec-32	25 dec-34 Dec-32 144ar-35	4.Jan 28 20.May 20 28.Apr 30	10-Jan-33 21-Feb-31 February 7, 2022	2 Responsible Party-Anyodas Tanmaceuticals S.A. 2	Cortact: Bayer Clinical Trials Cortact; Bayer Clinical Trials 2020/Trials Frank- cortact; or Locations Provided Cortact; Josef & Res, Mith/Cold0000021yag Bayerbi Cortact; Josef & Res, Mith/Cold000021yag Bayerbi Cortact; Josef Bayerbios Cortact; Josef Bayerbios Cortact; Josef Bayerbios Cortact; Josef Bayerbios	
 m the information of the second second	 An experiment of the T is built to be about the sector of the the the sector of the the sector of the the sector of the sector of	NCT94817036 NCT94286456 Clinicalfishinger McT9428668 NCT9425668	Bayer No Contacts or Locations Provided Spanner: AvtAl Branchning For Callaborator: Medgaco, No.	7-3420 Sep21 6 1-0ec-32 3-May-30	23 dec 34 Dec 32 1 Mar 35 21 dec 34	4-Jan 20 20-May 20 20-Apr 20 22-Jan 20	10-Jan-23 31-Feb-21 February 7, 3022 36-Jan-22	2 Responsible Party Annyedia hamaousiciali S.A. 2 Study Clair/Metthieu abaudatishivensiby Ferrand	Gortan: Bayer Clinical Frain Children (1998) 2003/1998 Bell 2003/1998 Bell 2003/1998 Bell 2003/2003/2003/2003/2003/2003/2003/2003	
en en Safty af Abdel Marine Safty af Abdel Safty and Safty af Abdel Marine Safty af Abde	 In the start of th	NCT94827035 NCT94826456 Clinicalfitude.gov NCT94326408 NCT94326408 NCT94328408	Bayer No Caracto or Location Provide Caliborator Melgano, Inc. Ubioentity Hospital, Clement ferrand	7-345-20 50p-31 ⁴ 1-0ec-32 3-May-30 23-Feb-20	25 dec 34 Dec 32 1 Mar 35 25 dec 34 1 Jan 33	4-Jan 20 20-May 20 28-Apr 30 23-Jan 20 13-Jan 20	10-Jan-33 31-Feb-21 February 7, 3052 36-Jan-32	2 Bergonichie Perty Annychie Parmaowsicoli S.A. 2 Sinaly Gasti Metty Bergani Percent Percent Michael Commen- Percent Michael Commen- Michael Commen- Commen- Commen- Michael Commen- Michael Commen- Commen- Michael C	Contract, Hay Child Think Contract, Hay Hay Child Children, Hay Children Children, Hang Children Contract Liver Billing Contract: Liver School Contract Contract: Liver School Contract Contract: Liver Billing Contract: Live	
 in a long report particular disease in the second se		scTool200 scTool200 coscTool200 scTo	Eger And Earthough Control of the Control Control of the Control of the Control Control of the Control of the Control Control of the Control of the Contro	7.0420 Sep21 2.0ec22 2.34eo20	35 Dec 34 Dec 33 14 Mar 25 13 Dec 34 1-3 arc 34 Dec 33	4.3an.28 20.May.38 23.3an.20 17.3a639	10-3am23 21-Febr21 8 26-3am22 26-3am22 11-May-21 23-Aug-22	2 Beginalia termanologi K. A. 2 Nongi Mendida and M. M. Kangal Mendida and M. Mendida and Mendida a	Gener Beyer Generation Statistics Description of the statistics Description of the statistics Provide Statistics Control Statis	
 in a long of school and school		x1144235 x1144346 x1144346 x1144346 x1144346 x1144347 x1144347 x1144347	Bayer Its Contains of Market States of	7.3430 Sep21 2.34923 2.34923 2.34923 2.34923 2.34924 2.34924	11 Sec 34	+ 3,00 - 20 - 30 May - 20 - 30 Ango - 20 - 22 Janes 20 - 17 Janes 20 - 10 Janes 20 - 36 Janes 20 - 36 Janes 20	23.300.23 21.606.21 806.0007 27 23.300.22 23.400.23 23.20 23.400.23 23.20 23.20 23.20 23.20 23.20 23.20 23.20 23.20 23.20 23.20 23.20 23.20 24.20 25.2	2 Reproduction for the second	near Byellow Taking San	
n e i de grad para de la construir de la const		ктинина кланина осколородо ведовала кланина кланина кланина кланина кланина кланина	ber bereinen sonnen sonne	7-3-6-20 Sep 21 2-10-c-22 2-24-0-2-0 4 4 4 4 4 4 4 5 2-24-0-2-0 2-24-0-2-0 4 5 2-24-0-2-0 2-24-0-	21 0xc 34 0xc 32 140x 35 140x 34 140x 34 14	43m38 2040y38 224m30 173449 164m48 164m48	23.4m23 21.6m21 644my27 2022 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 24.4m22 25.4m23 25.4m33 2	2 Proposition Proposition Constraints of the second Constraints of the second Proposition of the	near Byolan ha Characteria (Salan Sala Basalagen and Basalagen and Basal	
 a. A. Superson and A. Superson an		x1340334 x1340644 C15405444 x1340548 x134055656 x134055656 x134055656 x1340556565656565655656565656565656565656	ber bereinen sonnen sonne	7.5430 Sep21 2869-20 23.6409-20 23.6409-20 4 4 4 4 4 4 5.6409-20	21 dec 34 14 dec 35 14 dec 34 14 dec 34	44053 2340y3 2340y3 2340y3 13449 13449 13449 13449 13449	23.4m23 21.6m21 40.4m27 2007 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 23.4m22 24.4m23 23.4m23 23.4m23 23.4m23 23.4m23 23.4m23 24.4m33 24.4m33 2	2 Proposition Proposition Control of the control of the control of the control of	oner spectra for characteristic sector spectra for spectra for spect	
 a. A. Say and S. Say and Say an		 x13441334 x13444344 x13444344 x13443444 	ber Lectorsweiter L	7.4430 50p31 2010y20 2016w2	21 dec 24 Bec 22 1 dec 24 1 dec 2	+ 4 an 28 20 May 28 20 An 20 10 Jak 20 1	23 Am23 24 Feb24 26 Jan 27 26 Jan 27 28 Jan 28	2 Supported Sector 1.1 Support	oner spectra for the second se	
 a. A. Say and S. Say and Say	 In the second sec	 K194036 K194056 K194056	ber Lectors with Lectors with Construction Constructio	7.4420 50921 2016022 2156020 2156000 2156000 2156000000 215600000 2156000000000000000	22 dec 4 Re: 22 14 dec 25 13 dec 34 14 dec 35 14 dec 34 14 dec 34 14 dec 34 14 dec 34 14 dec 34 14 dec 34	4 4 an 28 2 3 4 4 an 24 2 2 4 4 an 24 2 3 4 an 24 2 3 4 an 24 2 3 4 an 24 2 3 4 an 24 2 4 4	23 Am23 24 Am23 Antenna 7, 24 Am22 24 Am22	2 Supported for the second sec		
n e la que parte sala de la que se a la que se la que se la que se a la que se a la que se		 KTHHIMH KTHIMH KTHIMH KTHIMH KTHIMH 	by control of the second seco	7.4420 50923 2.140420 3.340420 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5	13 dec 34 Be 23 1 dec 34 1 dec 34	+ Jan 38 2044ay 30 2044ay 30 2044ay 30 1044ay 30 1	23.4m23	, survey of the second		
	besedup dama under a fau base base and a set of the	x1344334 xC344464 xC344464 xC3444644 xC3444644 xC3444444 xC3444444 xC3444444 xC34444444 xC34444444 xC34444444 xC34444444444	by Internet and a second seco	7.440 5023 2010-22	13 dec 34 14 e 23 14 e 24 14 e 25 14 e 24 14 e 24 1	+ Jan 34 2 May 43 2 Jan 24 2 Jan 24 1 Jad 47 1 Jad	33.4m23	, s	one species and a species and	

ACIN-IN-Theoperatics for feesting the paraliest XIII COM as (TMACO)	The end white the web parameters of the second seco	NCTRERETISE	Seponar: Bennari Alarga sol telestisa Sonare (MAR) Collaboratori International Research Collaboratori International Research Notifield Research Condi- Scilly Institute Waldwigen D.C. Venezus Alaria Modeldal Scilly Institute Waldwigen D.C. Network (Scill) Collegations of the Resident Institute ALGS Clinical Trails Collegations of the Network (Scill) Collegations of the Water Scill Scilly Institute Water Scill Sciences (Scill) Glinad Sciences (Scill)	20-Apr-21	74av-22	18-Apr-31	19-Dec-22	Fringpal Bower, Stransel Bower, Marchan Kang, Sanger,	1 2	affinis Bergene brieve by and an initial biblioter. Anatologue
VERU-111 in the Treatment of SARS-Cov2 Infection by Associating Int Effect on the Proportion of Patients Who Die on Study (VERU-111)	To demonstrate the efficacy of VGRU-111 in the treatment of SARG-Cov-3 Infection by assessing its effect on the proportion of patients: who die on study (prior to Day 60).	NCT04642747	Weru Inc.	18-May-21	6-346-22	13-4pr-31	26-Aug-22	Study Chair Sametteviena Inc.	2	Ministra the Transmer of Mill Car Jackston in Jackston in The an electronic of Science Million in the Last Tartane. Association are
Safety and Efficacy of USB002 for Respiratory Distress Due to COM 19	This shall will shady the use of USB000 given as an introvenous influion in patients with respiratory distress due to inflocion with COVID-00.	NCT04778059	US Biotest, Inc.	27-346-21	Mar-23	246ar-25	10-Jan-22	Principal Investigator Sairam Parthasarathy, M2The University of Arizona Health Sciences Center/ Banner Healthcare Systems Hospital	71he University of Arizona Health Sciences Center/Ranner Healthcare Systems Hospitalis Tucson, Arizona, United States, 85724	lang and Direct and Still Technique and State Street in Still and State Street Street Street
Ganciciosir to Prevent Reactivation of Cytomegalowirus in Patients With Acute Respiratory Palare and Septis (GRAL*1)	This is a phase 3 ctudy designed to evolutions whether the administration of guidCode viceousses vertilators the days in immunosympteter grainess with spoils associated acute registratory failure. Sur hypothes in the Y guidCode acuteria section of the test linears associated acuter registratory failure in the test associated acuteria section of the test linears associated acuteria section of the test linears associated acuteria section of the test linear outcomes.	NCT04706507	Spansor: Free Hutchiston Cancer Center Callaborator: National instruction National instruct (NetAil)	29-Jun 21	21-Aug-27	12-140-21	13-34622	Principal Investigator/Michael Roeckh, MDFred Hutchinson Canzer Center	Contact: Michael Boekh, M0206 667 6756mboekh@thedhuch.org Contact: Losies Kimball, PRD, JR206 667 2956Kimball@thedhuch.org	
Empirical Steedst and/or Antifungals in Immusecompromised Patients With Acute Respiratory Failure From Undetermined Efology: a Multicenter Double-blind Randomized Controllad Yial (EFRAM II)	The main objective of this study is no reduce the 60-day mortality is immunocompromised patients with A66 from undetermined eticlogy at day-1. The intervention would environ the impact of ceretide a insuccessable for 54 days or until ICU discharge.	NCTONGOUGH	Amistance Publique - Hôpitaux de Paris	21 Oec-20	25 Dec -23	23-0ec-20	23-Dec-20	,	Contact: Elle Azoulay, Pr+321 62-69-34 23ele azoulay Bayto, fr Cottact: Matthies Reach Rean Pr+32562490742matthies reac he rigon@univ.paris.ddetat.fr	jada bada ada tekan kumanan dar ben yai kan karan (An far nar-matikan kutan kutan katika karartan da bat ya Ba
Study of Niclocamide in Hoderati and Seven Hospitalized Coronavirus-19 (COVID-19) Patients	This is a 2 part, Phase 2/8 multi-center, double blinded, plaste-controlled study to assess the safety, talenability, and efficary of oral niclosamide (MMADD) in moderate and evene haspitalized CVUID-98 patients compared to placebo.	NCT04623924	Neurolio Pharmaceuticals inc.	7-0(1-20	Dec-22	27-0ct-20	26-Apr-32	Study Director Doug Rank, MDNeurolio Pharmaceuticals	Andrew Bartymkii 650 263- 1270andrew@neurobopharma.com	
Efficacy of BCKamethasone in Patients With Acute Hypaxemic Bioplastory Fallare Caused by Biffictions (DDA-REFINE)	This is a multicenter, randomiand, controller, open-lobel dision's risk teering desametrissone in metassically ventisets adult privates, with established AVAP (notaviding AVAP) courses by confirmed privatesary or optimistic influctions, admitted in a network of Spanish ICOX	NCT/4545242	Sponsor: Dr. Negrin University Hospital Goliabontors: Li Ka Shing Knowledge Institute Consorio Centro de Investigación Biomédica en Red, M.P.	63621	30 Dec -23	10-Sep-20	23-Mar-22	Principal Investigator:Jeak Villar, MDHospital Universitaris Dr. Negrin	Contact: Jesis Villar, MD-36506800037jesus villaris @gmail.com Contact: Arthur Sutsky, MD-145623400004rthur Suts ky@unitybealth.to	Ban (Theolem 1999) We have Berger been been been after a the two Banthalan.
BRD 300 Chal Surgension is Previously Hospitalized Long COVID Patients	This is a randomized, double-blinded, placebo- contrained, two-arm study to evaluate the suffery and efficacy of 100 Col frain Sequerion (100 Col 10) as a therapy to improve lung function in patients that were houpstailed for were COVID 6-break liness and continue to experience goot-actor expiratory complications associated with long COVID after distance.	NCT04482585	Sponsor: Humanetics Corporation Collaborators: NYU Langone Health National Institute of Allengy and Infectious Diseases (WAID)	11-809-30	30 Nov-23	22145-20	2.4ug-22	,	Michael D Kaytor, Ph.D.963-400 Oldömkaytor (jhumaneticuorp. com	Marine a second and any descent second second a second s
Universil Anti-Visal Vaccine for Healthy Edeniy Adults (ALLOPKINE)	This pretain text the arking and efficacy of a rowin universal vacation acrospy child "allopering" which is designed to precess which y shaft it home programsion of any type of valuel shefts, including provides precession against progression of the convect statement of Childh- il shefts, and any lawor statement that any protection is the councils sheft and values are precession from any fazare carrently achoes newly energets to may fazare carrently achoes newly energets	NCT04441047	Spansor: Immunovative Therapies, Izd. Calibborator: Mirror Biologics, Inc.	12-34-21	35 dec -23	22-Jun-20	31-Aug-32	Study Director:David Fineberg, MDMirror Biologics, Inc.	Contact: Kim Demonte, LPH1- 722-430- Oolikoolemoote (Photmail com Contact: Thu Jiu, MH43-450- 227-4872thu@mirrarbia.com	annan da san anna anna an an an an annan an an an
Efficacy and Safety of Yosorakimat in Patients Hospitalised for Viral Long Infection Requiring Supplemental Oxygen (IILIA)	The purpose of this study is to evaluate the effect of toronakinab as an add-on to SoC in parimetry with viral lung inflection requiring supplemental suppro on the prevention of death or progression to IMV/ECMO.	NCT05634450	Atraženeca	13-0ec-22	9May-24	22-Nov-22	20-0ec-22	,	Astraženeca Clinical Study Information Center1407-340- 9429information.center@astraz eneca.com	taan tahun kaatu ka kana da ka ku
A Study of Micro Dose Ambrisentan in Norpitalized Patients With Respiratory Insufficiency Due to COMD-19	This study will evaluate whether ambrientan, by blocking the effects of the hormone endothelin in the lungs, improves the breathing capacity of parasets with COVID-16, increase the concentration of ougges in the blood and prevents the progression to respiratory billure and death.	NCT14771000	Noorik Biopharmaceuticals AG	8-Feb-21	31-34-23	25-Feb-21	20-Oct-22	Principal Investigator/kok Civijak, MDDIsiversity Hospital for Infectious Diseases Fran Mihaljevic	iker Navarra, MD+61 76 288 7007iker navarra@noorik.com	<u>Line of the Industry Standards Constitutions with Standards Institutions for a Unit of the Tay Standards and </u>